Compare Trip.com Group Ltd (TCOM) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Trip.com Group Ltd vs Twist Bioscience Corp — how do they compare? Trip.com Group Ltd trades at $43.78 (market cap $28.12B), while Twist Bioscience Corp trades at $88.31 (market cap $5.45B). The key difference: Trip.com Group Ltd is far larger — about 5.2× Twist Bioscience Corp's market cap, and Trip.com Group Ltd pays a 0.42% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| TCOM | TWST | |
|---|---|---|
Market Cap | $28.12B | $5.45B |
Sector | Consumer Cyclical | Health |
52-Week High | $78.96 | $102.88 |
52-Week Low | $39.84 | $24.16 |
Enterprise Value | $20.82B | $5.37B |
Dividend Yield | 0.42% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Trip.com Group Ltd
Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Prior to the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from websites and mobile platforms, while the rest come from call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Toncheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
Read more on TCOM →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
